Connect with us

CBD News

Elixinol Global Unloads Nearly 13 Million Shares to Fuel CBD Oil and Hemp-Derived Product Growth

Denis Mariti



Elixinol Respira CBD Oil

12.8 Million Shares Sold by Elixinol Global at A$3.90 to Fund CBD Growth

Yesterday, June 4th, 2019, Elixinol Global requested that trading be paused in connection with a raise in capital, expecting that halting the trade might last through Wednesday, June 5th. Yesterday evening, the company announced that it had generated $50 million through selling shares at A$3.90 in a deal that Bell Potter Securities led.

Paul Benhaim, the CEO of Elixinol Global, issued a statement acknowledging the support of the new and existing institutional investors in accelerating the company’s expansion in the United States and across the globe. Benhaim noted that the company is witnessing an unprecedented positive shift in buyer’s appetite for CBD and products derived from hemp.

Benhaim went on to say that Elixinol is planning to double its current US production capacity. By acquiring additional raw materials, this company will be in a position to accelerate the growth of strategic opportunities and Elixinol branded CBD products.

The capital raise is the third and biggest raise of the company. Late 2017, Elixinol had raised $20 million by completing an IPO at $1.00. In September, it sold shares at $1.85 and raised $40 million. Later in April, the stock traded at an overwhelming $5.93.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.


Follow Times of CBD News

popular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.


Trending CBD News